共 50 条
- [1] An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Vandross, Andrae L.Stein, Brian N.Coward, JermaineSharma, SunilJohnson, Amy J.Birkett, JosephHuang, XinFrigault, Melanie M.Lerchen, Hans-GeorgStelte-Ludwig, BeatrixNavarro, TashedaPeck, JimGross, WyattIzumi, RaquelHamdy, Ahmed M.Rivera, Ildefonso Rodriguez
- [2] A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Fathi, Amir TahmasbDonnellan, William BruceLyons, Roger M.Maris, Michael B.Kim, Tae MinKim, Won SeogSchiller, Gary J.Abboud, Camille N.Arellano, Martha LuciaCull, Elizabeth H.Yee, Karen W. L.Townsley, Danielle MichelleWang, FujunBothos, John G.Yao, Nai-ShunSalles, Gilles A.
- [3] A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors: initial findingsCANCER RESEARCH, 2016, 76Bauer, Todd M.Jones, Suzanne F.Greenlees, CarolCook, CarlMugundu, Ganesh M.Jewsbury, Philip J.Pierce, Andrew J.O'Connor, Mark J.Johnson, Melissa L.Beck, J. ThaddeusMoore, Kathleen N.Hart, Lowell L.Infante, Jeffery R.Burris, Howard A.Spigel, David
- [4] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label studyINTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1795 - 1804Kondo, ShunsukeIwasa, SatoruKoyama, TakafumiFujita, TomokoSugibayashi, KoMurayama, KoshoYamamoto, Noboru
- [5] Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label studyInternational Journal of Clinical Oncology, 2022, 27 : 1795 - 1804Shunsuke KondoSatoru IwasaTakafumi KoyamaTomoko FujitaKo SugibayashiKosho MurayamaNoboru Yamamoto
- [6] Safety, tolerability, pharmacokinetics, and antitumor activity of adavosertib in Japanese patients with advanced solid tumors: A phase I, open-label studyCANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 39Kondo, ShunsukeKatsuya, YukiYonemori, KanKomuro, KeikoSugeno, MasatoshiKawata, ToshioGhiorghiu, DanaMeulendijks, DidierYamamoto, Noboru
- [7] A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Haydon, Andrew MarkKichenadasse, GanessanKirkwood, John M.Kaufman, Howard E.Buchbinder, Elizabeth IannottiGanju, VinodBarve, Minal A.Jiang, HaifangXu, HuinanZhou, XushaZhu, Huan J.Ni, DongyaoNiu, Jiaxin
- [8] A phase I study to evaluate safety, tolerability, pharmacokinetics and activity of oraxol in patients (pts) with advanced malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Ma, Wen WeeAzad, Nilofer SabaLam, Elaine TatDiamond, Jennifer RobinsonDy, Grace K.Opyrchal, MateuszGallagher, DeniseBrennen, CadenCutler, DavidKramer, DouglasChan, Wing KaiKwan, RudolfFetterly, Gerald J.Adjei, Alex A.Jimeno, Antonio
- [9] A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Rule, SimonKater, Arnon P.Brummendorf, Tim H.Fegan, ChrisKaiser, MartinRadford, John A.Stilgenbauer, StephanKayser, SabineDyer, Martin J. S.Brossart, PeterCidado, JustinDrew, LisaBirkett, JoeDavies, AndrewShao, WenlinBrugger, Wolfram
- [10] A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Lim, Emerson A.Bauer, Todd MichaelPatel, Manish R.Falchook, Gerald StevenKarlix, Janet L.Choe, Jennifer HsingGeorge, Daniel J.Mugundu, Ganesh M.Pilling, ElizabethChen, HuifangLinghu, BolanMcGrath, LaraShao, WenlinMerchant, Melinda S.Sidders, BenSachsenmeier, Kris F.Pouliot, Gayle PageauDrake, Charles G.Bendell, Johanna C.